Urinary bladder small cell neuroendocrine carcinoma
diseaseOn this page
Also known as bladder small cell neuroendocrine cancerbladder small cell neuroendocrine carcinomapoorly differentiated neuroendocrine carcinoma of the bladderSCCBsmall cell bladder cancersmall cell bladder carcinomasmall cell carcinoma of the urinary bladdersmall cell carcinoma of urinary bladdersmall cell neuroendocrine carcinoma of the urinary bladdersmall cell neuroendocrine carcinoma of urinary bladderurinary bladder small cell carcinoma
Summary
Urinary bladder small cell neuroendocrine carcinoma (MONDO:0004114) is a cancer and 3 clinical trials. Top therapeutic interventions include cabozantinib and ipilimumab. A subtype of small cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Prevalence: <1 / 1 000 000 (Europe) [Orphanet-validated]
- Phenotypes (HPO): 6
- Clinical trials: 3
Clinical features
Epidemiology
Prevalence records
3 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | <1 / 1 000 000 | Europe | Validated | |
| Annual incidence | 1-9 / 1 000 000 | 0.14 | United States | Validated |
| Point prevalence | <1 / 1 000 000 | Europe | Not yet validated |
Signs & symptoms
Clinical features (HPO)
6 HPO clinical features (Orphanet curated; top 6 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0000790 | Hematuria | Very frequent (80-99%) |
| HP:0009725 | Bladder neoplasm | Very frequent (80-99%) |
| HP:0100518 | Dysuria | Frequent (30-79%) |
| HP:0002027 | Abdominal pain | Occasional (5-29%) |
| HP:0003072 | Hypercalcemia | Occasional (5-29%) |
| HP:0000010 | Recurrent urinary tract infections | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | urinary bladder small cell neuroendocrine carcinoma |
| Mondo ID | MONDO:0004114 |
| EFO | EFO:1000129 |
| Orphanet | 284400 |
| DOID | DOID:7132 |
| NCIT | C9461 |
| UMLS | C1332564 |
| MedGen | 231950 |
| GARD | 0011923 |
| Anatomy (UBERON) | UBERON:0001255 |
| Is cancer (heuristic) | yes |
Also known as: bladder small cell neuroendocrine cancer · bladder small cell neuroendocrine carcinoma · poorly differentiated neuroendocrine carcinoma of the bladder · SCCB · small cell bladder cancer · small cell bladder carcinoma · small cell carcinoma of the urinary bladder · small cell carcinoma of urinary bladder · small cell neuroendocrine carcinoma of the urinary bladder · small cell neuroendocrine carcinoma of urinary bladder · urinary bladder small cell carcinoma
Disease family
This is a subtype of small cell carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › neuroendocrine carcinoma › small cell carcinoma › urinary bladder small cell neuroendocrine carcinoma
Related subtypes (17): extrahepatic bile duct small cell adenocarcinoma, ovarian small cell carcinoma, colon small cell neuroendocrine carcinoma, esophageal small cell neuroendocrine carcinoma, ampulla of vater small cell neuroendocrine carcinoma, Bartholin gland small cell carcinoma, thymus small cell carcinoma, cervical small cell carcinoma, endometrial small cell carcinoma, gallbladder small cell neuroendocrine carcinoma, gastric small cell neuroendocrine carcinoma, laryngeal small cell carcinoma, pancreatic small cell neuroendocrine carcinoma, prostate small cell carcinoma, salivary gland small cell carcinoma, ureter small cell carcinoma, small cell lung carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 3.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 2 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03866382 | PHASE2 | RECRUITING | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors |
| NCT02496208 | PHASE1 | ACTIVE_NOT_RECRUITING | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors |
| NCT03582475 | PHASE1 | ACTIVE_NOT_RECRUITING | Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CABOZANTINIB | 4 | 4 |
| IPILIMUMAB | 4 | 2 |
Related Atlas pages
- Drugs: Cabozantinib, Ipilimumab